JP6949668B2 - Absorbent article - Google Patents

Description

The present invention relates to an absorbable article for menstrual blood absorption.

For absorbent articles for menstrual blood absorption such as sanitary napkins, the diffusion of menstrual blood in the plane direction is controlled by a leak-proof groove in which the surface sheet and the absorber are integrally recessed to prevent absorption and leakage. Performance is being improved.
For example, it is widely practiced to provide a pair of lateral leak-proof grooves extending in the vertical direction of the absorbent article on both sides in the vertical direction to prevent menstrual blood from leaking from both ends in the horizontal direction of the absorber. There is. In addition, leak-proof grooves extending in the lateral direction are provided in the front portion and the rear portion of the absorbent article to prevent menstrual blood from leaking from both ends in the vertical direction of the absorber.

Further, a technique is known in which a fluid treatment agent for absorbing menstrual blood is applied to an absorbent article to improve the absorption performance of menstrual blood. For example, Patent Document 1 discloses a menstrual zone including an absorbent pad containing a salt of a polyvalent ion. In addition, the applicant has previously proposed an absorbent article containing a blood coagulant containing a water-soluble metal compound in an absorbent core (see Patent Document 2).

Special Publication No. 38-17449 Japanese Unexamined Patent Publication No. 2005-287997

However, if a leak-proof groove extending in the lateral direction is provided in the front portion or the rear portion of the absorbent article as the leak-proof groove, the diffusion of menstrual blood beyond the leak-proof groove is suppressed, and as a result, the diffusion of menstrual blood beyond the leak-proof groove is suppressed. Many parts that do not absorb the liquid remain in the absorber, and the utilization efficiency of the absorber is reduced.
In addition, when a blood cell flocculant having a high ability to form erythrocyte agglutinates is placed in the entire absorption region of the napkin, the present inventors have red blood cells on the sides and anterior-posterior parts of the napkin. It was found that the taste was strong and the wearer may be worried that a leak might have occurred when the napkin was removed and viewed after use.

An object of the present invention relates to providing an absorbent article capable of solving the above-mentioned problems of the prior art.

The present invention includes a liquid-permeable front surface sheet that forms a skin-facing surface, a back surface sheet that forms a non-skin-facing surface, and an absorber arranged between both sheets, and is provided in the vertical direction along the front-back direction of the wearer. And an absorbent article for menstrual blood absorption having a horizontal direction orthogonal to the vertical direction, in which the surface sheet and the absorber are integrally recessed as a leak-proof groove, in which the wearer's liquid excretion portion faces each other. Lateral leak-proof grooves formed on both left and right sides of the arranged excretion spot portion, respectively, and front and rear of the excretion spot portion extending in the vertical direction, respectively, in the front and in the lateral direction. It has a rear leak-proof groove, and forms a surface of the absorber on the skin-facing surface side, or a blood cell flocculant is arranged on a member located on the skin-facing surface side of the absorber. The blood cell flocculant is present in the excretion spot portion in the lateral direction and is arranged so as not to reach both ends of the collection in the lateral direction, and is arranged in the excretion spot portion in the vertical direction. It provides an absorbent article that is present and is located beyond at least one of the anterior and posterior leak-proof grooves.

According to the absorbent article of the present invention, it is possible to suppress liquid leakage from the lateral direction of the absorber, effectively utilize the absorption capacity of the absorber, and hemagglutination near the vertical end of the absorber. It is possible to prevent the user from worrying about leakage due to the redness of the lump.

FIG. 1 is a plan view of a sanitary napkin according to an embodiment of the present invention as viewed from the skin-facing surface side. FIG. 2 is a schematic cross-sectional view taken along the line II-II of FIG. FIG. 3 is a schematic plan view of the absorber of the sanitary napkin shown in FIG. 1 as viewed from the side facing the skin, and the portion where the blood cell flocculant is arranged is shown by a shaded portion. FIG. 4 is a view corresponding to FIG. 3 of an absorber of a sanitary napkin according to another embodiment of the present invention. FIG. 5 is an enlarged plan view showing an example of a leak-proof groove provided with a high-pressure squeezing portion and a low-pressure squeezing portion at the bottom.

Hereinafter, the absorbent article for absorbing menstrual blood of the present invention will be described based on the preferred embodiment thereof with reference to the drawings.
The sanitary napkin 1 (hereinafter, also referred to as napkin 1) according to an embodiment of the present invention is an absorbent article for absorbing menstrual blood, and forms a skin-facing surface as shown in FIGS. 1 and 2. It includes a liquid-permeable front surface sheet 2, a back surface sheet 3 forming a non-skin facing surface, and a liquid-retaining absorber 4 arranged between both sheets 2 and 3. The front surface sheet 2, the absorber 4, and the back surface sheet 3 are integrated to form the absorbent main body 5. Side leakage-proof sheets 6 are arranged on the surface sheet 2 sides of both sides of the absorbent body 5 in the longitudinal direction.
The side leakage-proof sheet 6 has a free end 61 not joined to the surface sheet 2 and a fixed end 62 joined to the surface sheet 2, and is between the fixed end 62 and the free end 61 at the time of use. Is separated from the surface sheet 2 to form a leak-proof pocket (not shown) that prevents lateral leakage. A main body adhesive portion (not shown) used for fixing the shorts to the crotch portion is provided on the surface of the absorbent main body 5 on the non-skin facing surface side. Further, the napkin 1 has a pair of wing portions 7 on both side portions in the vertical direction X. On the surface of the pair of wing portions 7 on the back surface sheet 3 side, a wing portion adhesive portion (not shown) used for fixing the crotch portion of the shorts to the non-skin facing surface is provided.

As the front surface sheet 2, the back surface sheet 3, and the side leakage-proof sheet 6, various types conventionally used for absorbent articles such as sanitary napkins can be used without particular limitation. For example, as the surface sheet 2, a non-woven fabric having a single-layer or multi-layer structure, a perforated film, or the like can be used. The surface sheet 2 may have irregularities on the side facing the skin, or may have an oil agent such as an agent for controlling hydrophilicity attached to the surface of the constituent fibers. When the surface sheet 2 has a multi-layer structure, the surface sheet 2 includes a first fiber layer located on the side closer to the wearer's skin and a second fiber layer located on the side farther from the wearer's skin. Both fiber layers are integrated in the thickness direction by a large number of partially formed joints, and a portion of the first fiber layer located between the plurality of joints is convex. A concavo-convex sheet that is raised to form the concavo-convex convex portion can be used. As the concavo-convex sheet having a solid structure in the convex portion, for example, those described in JP-A-2007-182662 and JP-A-2002-187228 can be used. As the back sheet 3, a resin film, a resin film, a non-woven fabric, a laminate, or the like can be used. As the back sheet 3, a liquid-impermeable (including poorly permeable) or water-repellent material is used, and it is also preferable to use a moisture-permeable resin film or the like. As the side leakage-proof sheet 6, a laminated non-woven fabric having high water pressure resistance, a laminated body of a resin film and a non-woven fabric, or the like can be used.

As shown in FIG. 1, the napkin 1 has a vertical direction X along the front-rear direction of the wearer and a horizontal direction Y orthogonal to the vertical direction X. Further, the napkin 1 has an excretion portion facing portion B having an excretion spot portion P arranged opposite to the wearer's liquid excretion portion such as the vaginal opening in the central portion in the lateral direction Y, and the front side of the wearer from the excretion portion facing portion B. It has a front portion A arranged on the side of the wearer and a rear portion C arranged on the rear side of the wearer from the excretion portion facing portion B. That is, the napkin 1 is divided into the front portion A, the excretion portion facing portion B, and the rear portion C in this order in the vertical direction X.

In the absorbent article of the present invention, the skin-facing surface is the surface of the absorbent article (napkin 1) that faces the wearer's skin side when worn, and the non-skin-facing surface is the absorbent article (napkin 1). , The surface that faces the side opposite to the skin side (usually the clothing side) when worn. The excretion spot portion P is a portion that is arranged to face the liquid excretion portion such as the wearer's vaginal opening when wearing an absorbent article such as a napkin 1 and directly supplies menstrual blood, and is usually described above. It is located at the center of the excretion portion facing portion B in the vertical direction X and the horizontal direction Y.

In the absorbent article of the present invention, the excretion portion facing portion B is a region having a wing portion in the vertical direction X of the absorbent article (one of them) when the absorbent article has a wing portion as in the napkin 1 of the present embodiment. It means a region sandwiched between the base of the wing portion along the vertical direction X and the base of the other wing portion along the vertical direction X). When the absorbent article does not have a wing portion, the central region when the absorbent article is divided into three regions by dividing the total length of the absorbent article into three equal parts is referred to as the excretion portion facing portion B. can do.

In the napkin 1, the front surface sheet 2 covers the entire area of the absorber 4 on the skin-facing surface side, and the back surface sheet 3 covers the entire area of the absorber 4 on the non-skin-facing surface side. In the front surface sheet 2 and the back surface sheet 3, the extending portions of the absorber 4 from both end edges in the vertical direction X are joined to each other. Further, in the back surface sheet 3 and the side leakage-proof sheet 6, portions extending outward in the horizontal direction Y from both side edges of the absorber 4 along the vertical direction X are joined to each other. In this way, the absorber 4 is sandwiched between the front surface sheet 2 and the back surface sheet 3, and the front surface sheet 2 or the side leakage-proof sheet 6 and the back surface sheet 3 are joined around the entire outer edge of the napkin 1. Any joining means such as an adhesive, a heat seal, and an ultrasonic seal is used for joining the sheets constituting the napkin 1.

As shown in FIG. 2, the absorbent body 4 of the napkin 1 of the present embodiment has an absorbent core 41 containing cellulosic hydrophilic fibers and a core wrap sheet 42 covering the absorbent core 41. ..
The core wrap sheet 42 is wound around the upper portion 42a that covers the skin-facing surface side of the absorbent core 41 and the non-skin facing surface side of the absorbent core 41, and is wound around the non-skin facing surface side of the absorbent core 41. It has a lower portion 42b that covers the surface. Further, the core wrap sheet 42 has an overlapping portion 42c between the sheets on the lower portion 42b.
As the core wrap sheet covering the absorbent core 41, one sheet may wrap the entire absorbent core 41, or two or more sheets may wrap the entire absorbent core 41. For example, the skin-facing surface side and the non-skin-facing surface side of the absorbent core 41 may be covered with separate sheets. Regardless of the number of sheets used to cover the absorbent core 41, the core wrap sheet covering the skin facing surface side of the absorbent core 41 is the skin side core wrap sheet 42a, and the non-absorbent core 41 is not. The portion that covers the skin facing surface side is also referred to as a non-skin side core wrap sheet 42b.

In the napkin 1 of the present embodiment, as shown in FIGS. 2 and 3, blood cells aggregate on the skin-side core wrap sheet 42a, which is the upper portion of the core wrap sheet 42 that covers the skin-facing surface side of the absorbent core 41. The agent is arranged. A blood cell flocculant is partially arranged on the upper portion of the core wrap sheet 42. That is, the skin-side core wrap sheet 42a has a flocculant-arranged portion 9 to which a blood cell flocculant is arranged and a flocculant non-arranged portion 9N to which a blood cell-aggregating agent is not arranged.

The skin-side core wrap sheet 42a is a member that forms the surface of the absorber 4 on the skin-facing surface side. Further, the skin-side core wrap sheet 42a is one of the lower members arranged at a position closer to the back surface sheet 3 than the front surface sheet 2 in the thickness direction of the napkin 1.
The flocculant arranging portion 9 containing the blood cell flocculant is a member located on the skin-facing surface side of the absorber 4 in the thickness direction of the absorbent article, or between the surface sheet 2 and the absorber 4. It may be formed in a sublayer (not shown) arranged as desired, but a sublayer (not shown) or skin which is a lower member located below the surface sheet 2 in the thickness direction of the absorbent article. It is preferably formed on the side core wrap sheet 42a, and is preferably formed on a member forming the surface of the absorber 4 on the skin-facing surface side, as in the napkin 1 of the present embodiment, and is particularly absorbent. It is preferably formed on the skin-side core wrap sheet 42a that covers the skin-facing surface side of the core 41.

Further, the blood cell flocculant may be contained in two or more members. For example, the aggregating agent arranging portion 9 containing a blood cell aggregating agent may be formed on the surface sheet 2 and the skin-side core wrap sheet 42a, or may be formed on the surface sheet 2 and a sublayer (not shown). , The surface sheet 2, the sub-layer (not shown), and the skin-side core wrap sheet 42a may be formed. Further, the flocculant arranging portion 9 containing the blood cell flocculant may be formed only on the skin side core wrap sheet 42a, but the non-skin side core wrap sheet 42b that covers the non-skin facing surface side of the absorbent core 41 may be formed. Also, a blood cell flocculant may be arranged.

As shown in FIG. 3, the skin-side core wrap sheet 42a on which the blood cell flocculant is arranged in the napkin 1 of the present embodiment is located at the central portion of the absorber 4 in the lateral direction Y in the excretion portion facing portion B. The coagulant arranging portion 9 is provided in the portion, and the coagulant non-arranging portion 9N is provided on both side portions of the absorber 4 located near both ends of the absorber 4 in the lateral direction Y.

The core wrap sheet is used for the purpose of improving the shape retention of the absorbent core, which is insufficient in shape retention by itself, and preventing the leakage of the constituent materials of the absorbent core, such as thin paper and non-woven fabric. Fiber sheet is used.
Examples of the cellulosic fibers constituting the thin paper include wood pulp fibers, rayon fibers, cotton fibers, and cellulose acetate fibers. Examples of the raw material pulp of the cellulosic fiber include wood pulp such as coniferous kraft pulp or broadleaf kraft pulp, and non-wood pulp such as cotton pulp or straw pulp. These cellulosic fibers may be used alone or in combination of two or more. Further, from the viewpoint of improving the strength, a small amount of non-cellulosic fiber can be mixed. Examples of non-cellulosic fibers include polyolefin fibers such as polyethylene and polypropylene, and condensed fibers such as polyester and polyamide. The proportion of cellulosic fibers in the constituent fibers of the thin paper is preferably 70% by mass or more and 100% by mass or less, more preferably 90% by mass or more and 100% by mass or less, and further preferably 100% by mass.

A non-woven fabric can also be used as the core wrap sheet. As the type of the non-woven fabric, a non-woven fabric produced by various manufacturing methods can be used without particular limitation. Examples thereof include air-through non-woven fabric, which is a non-woven fabric obtained by heat-sealing the constituent fibers of the fiber web by hot air treatment, and resin-bonded non-woven fabric, which is a non-woven fabric obtained by adhering the constituent fibers of the fiber web with an adhesive. Fiber webs of spunlace non-woven fabrics, air-through non-woven fabrics, and resin-bonded non-woven fabrics can be produced by a card machine, an air-laid method in which fibers are stacked in the air, or the like.

Raw material fibers for non-woven fabrics are made from cellulosic hydrophilic fibers such as wood pulp fibers, rayon fibers, cotton fibers, and cellulose acetate, and synthetic resins such as polyolefins such as polyethylene and polypropylene, polyesters such as polyethylene terephthalate, and polyamides such as nylon. Synthetic fibers can be mentioned. As the synthetic fiber, a core-sheath type or side-by-side type composite fiber can also be used. Among these, for the same reason as using thin paper, it is preferable that the raw material fiber is a cellulosic fiber even when the non-woven fabric manufacturing method is adopted. The proportion of cellulosic fibers in the constituent fibers of the non-woven fabric is preferably 70% by mass or more and 100% by mass or less, more preferably 90% by mass or more and 100% by mass or less, and further preferably 100% by mass. As the raw material fiber of the non-woven fabric, one kind may be used alone or two or more kinds may be used in combination.

The absorbent core 41 of the napkin 1 is preferably made of a mixed fiber of pulp fiber, which is a cellulosic hydrophilic fiber, and a highly absorbent polymer. The mixed fiber stack is manufactured by a known drum-type triple product device equipped with a fiber stacking drum having a stacking recess on the peripheral surface, and the circumference of the triple product drum is sucked from the bottom surface of the stacking recess. Pulp fibers and highly absorbent polymers as materials for forming the absorbent core are supplied to the surface in a scattered state, the material for forming the absorbent core is deposited in the recesses for accumulation, and then the mold is released from the recesses for accumulation. Can be obtained. The absorbent core 41 of the napkin 1 of the present embodiment may be a single-layered fiber which is a cellulosic hydrophilic fiber that does not contain a highly absorbent polymer.

The cellulosic hydrophilic fibers constituting the absorbent core 41 include non-wood pulp fibers made from non-wood such as wood pulp fibers, cotton pulp or straw pulp, rayon fibers, cotton fibers, cellulose acetate and the like. Fiber is mentioned. These fibers may be used alone or in combination of two or more. From the viewpoint of improving strength, the absorbent core 41 includes, in addition to cellulose-based hydrophilic fibers, polyolefin-based fibers made of polyolefin such as polyethylene and polypropylene, and synthetic fibers such as polyester fibers and condensed fibers such as polyamide. You may mix a small amount. In the absorbent core, the proportion of cellulosic hydrophilic fibers, particularly wood pulp fibers, is 100% by mass or less, preferably 50% by mass or more and 95% by mass or less, more preferably, based on the total mass of the absorbent core. Is 60% by mass or more and 90% by mass or less, more preferably 70% by mass or more and 80% by mass or less.

As in the present embodiment, the absorbent core 41 may contain a super absorbent polymer (water-absorbing polymer). As the highly absorbent polymer, a particulate polymer is generally used, but a fibrous polymer may also be used. When a particulate high-absorbent polymer is used, its shape may be spherical, lumpy, bale-shaped or amorphous. As the highly absorbent polymer, a polymer or copolymer of acrylic acid or an alkali metal salt of acrylic acid can generally be used. Examples thereof include polyacrylic acid and salts thereof, and polymethacrylic acid and salts thereof. As the polyacrylate or polymethacrylate, a sodium salt can be preferably used. In addition, acrylic acid or methacrylic acid, maleic acid, itaconic acid, acrylamide, 2-acrylamide-2-methylpropanesulfonic acid, 2- (meth) acryloylethanesulfonic acid, 2-hydroxyethyl (meth) acrylate, styrenesulfonic acid, etc. A copolymer obtained by copolymerizing the comonomer of the above in a range that does not deteriorate the performance of the highly absorbent polymer can also be used. In the absorbent core, the proportion of the highly absorbent polymer is preferably 5% by mass or more and 50% by mass or less, more preferably 10% by mass or more and 40% by mass or less, still more preferably 15% by mass, based on the total mass of the absorbent core. It is 30% by mass or less. Since the absorbent core 41 contains a super absorbent polymer, the absorbent core 41 can more stably quickly absorb and retain a large amount of excrement liquid such as blood. Further, the absorbent core 41 may be blended with a deodorant, an antibacterial agent, or the like, if necessary. The amount of the deodorant and the antibacterial agent to be blended in the absorbent core 41 is not particularly limited, and may be the amount normally blended in the technical field.

The method for incorporating the hemagglutination agent into the constituent members of the napkin such as the core wrap sheet 42 is not particularly limited, and for example, a hemagglutination agent containing a cationic polymer is appropriately added to water, ethanol, a mixed solution thereof, or the like. It is possible to dissolve the solvent in the above, attach it to a desired part of the constituent member as a solution, and then dry it to remove the solvent. It is preferable because it is carried out in a series of production lines continuous with the production process together with the process, and the hemagglutination agent can be easily applied to the sheet to be coated at a desired concentration.
As a method of adhering the solution to the constituent member, it is possible to adopt a method of dropping the solution onto a predetermined portion of the constituent member and various coating methods. For example, a spray method, a dipping method, a transfer method, a die coating method, a gravure coating method, an inkjet method, a screen printing method, or the like may be used to apply a liquid to a predetermined portion of a component using a known liquid coating apparatus. .. Further, the drying may be any of drying by heating, drying by reduced pressure, and drying by combining heating and reduced pressure, but natural drying may be used instead of these forced drying.

In order to form the flocculant-arranged portion 9 and the coagulant-non-arranged portions 9N located on both sides of the coagulant-arranged portion 9 on the skin-side core wrap sheet 42a, the core is coated with the blood cell flocculant on the strip-shaped core wrap sheet continuum. The blood cell flocculant is applied only to the portion arranged in the central portion in the width direction of the absorber 4 in the width direction of the wrap sheet continuum. The core wrap sheet continuum coated with the blood cell flocculant is superposed on the absorbent core 41 to form a continuous body of the absorber 4, and then cut into the dimensions of individual absorbent articles and incorporated into the napkin 1.

As shown in FIGS. 1 and 2, the napkin 1 of the present embodiment has lateral leakage-proof grooves 81 extending in the vertical direction X on both sides of the vertical center line CL of the napkin 1 on the skin-facing surface of the napkin 1. , 81. The lateral leakage-proof grooves 81 and 81 are formed at least in the excretion portion facing portion B, and the excretion portion facing portion B extends in the vertical direction X on both sides of the excretion spot portion P. The lateral leak-proof groove 81 preferably extends from the excretion portion facing portion B to the front portion A or the rear portion C, and as shown in FIG. 1, the front portion A, the excretion portion facing portion B, and the excretion portion facing portion B. It is more preferable that it extends over the rear portion C, but it may be formed only on the excretion portion facing portion B.

Further, the napkin 1 of the present embodiment has a front leak-proof groove 82 and a rear leak-proof groove 83 on the skin facing surface of the napkin 1 in front of and behind the excretion spot portion P. The front leak-proof groove 82 is formed in front of the excretion spot portion P, crosses the vertical center line CL to the left and right, and extends in the lateral direction Y of the napkin 1. The rear leak-proof groove 83 is formed behind the excretion spot portion P, crosses the vertical center line CL to the left and right, and extends in the lateral direction Y of the napkin 1.
It is preferable that the front leak-proof groove 82 and the rear leak-proof groove 83 each cross at least the vertical center line CL of the napkin 1 in the horizontal direction Y. As shown in FIG. 1, the front leak-proof groove 82 preferably has a circular arc shape that is convexly curved toward the front, and the rear leak-proof groove 83 has an arc shape that is convexly curved toward the rear. Is preferable.
Here, with respect to the front leak-proof groove 82 and the rear leak-proof groove 83, extending in the lateral direction Y means extending substantially in the lateral direction Y as a whole, and extends linearly in the lateral direction of the napkin 1. It may be curved toward the front, curved toward the rear, and further, a curved portion that is convex toward the front and a curved portion that is convex toward the rear. May be a leak-proof groove formed continuously in the lateral direction.

Each of the lateral leakage-proof grooves 81 and 81 has a plan-view shape that is convexly curved toward the outside in the lateral direction Y at portions located on both sides of the excretion spot portion P with the excretion spot portion P in between. A front arcuate portion 81a and a rear arcuate portion 81a having an arcuate portion 81b and having a plan view shape curved outward in the lateral direction Y before and after the central arcuate portion 81b in the vertical direction X, respectively. It has an arcuate portion 81c. Each of the lateral leakage-proof grooves 81 and 81 has a plan view shape in which the three arcuate portions 81a, 81b and 81c curved outward in the lateral direction Y are connected in the vertical direction X. The distance between the pair of lateral leakage-proof grooves 81 is the distance between the connecting portion between the central arc-shaped portion 81b and the front arc-shaped portion 81a and the connecting portion between the central arc-shaped portion 81b and the rear arc-shaped portion 81c. It is a narrowed constriction.
Further, a second lateral leakage-proof groove 84 is provided outside the lateral leakage-proof groove 81b of each of the side leakage-proof grooves 81 and 81 in the lateral direction Y. The second lateral leakage proof groove 84 has a plan view shape that is convexly curved toward the outside in the lateral direction Y, similarly to the central arcuate portion 81b of the side leakage proof groove 81. The central arcuate portion 81b of the side leakage prevention groove 81 and the second side leakage prevention groove 84 on the outer side thereof are formed side by side in the lateral direction Y, and are formed substantially parallel to each other.
The side leakage prevention groove 81, the front leakage prevention groove 82, the rear leakage prevention groove 83, and the second side leakage prevention groove 84 are all the side leakage prevention groove 81 and the second side leakage prevention groove shown in FIG. Like 84, the surface sheet 2 and the absorber 4 are integrally recessed, and each leak-proof groove is, for example, a surface of a stack of the surface sheet 2 and the absorber 4. It can be formed integrally from the sheet 2 side by pressurizing or embossing with heating and pressurization.

In the napkin 1 of the present embodiment, the hemagglutin agent arranged on the skin-side core wrap sheet 42a is present in the excretion spot portion P and is an absorber in the lateral direction Y of the napkin 1, as shown in FIG. It is arranged so as not to reach both ends 4S in the horizontal direction, and in the vertical direction X, it exists in the excretion spot portion P and exceeds the position of the front leak-proof groove 82 and the position of the rear leak-proof groove 83. Is arranged up to. More specifically, the skin-side core wrap sheet 42a has a coagulant-arranged portion 9 at the center of the absorber 4 in the lateral direction Y, and has coagulant-non-arranged portions 9N on both the left and right sides thereof. .. Further, in the present embodiment, the coagulant arranging portion 9 continuously extends from the excretion spot portion P to a position beyond the front leak-proof groove 82, and in the front portion A, the front leak-proof groove 82 is vertically X. It traverses to. Further, the coagulant arranging portion 9 continuously extends from the excretion spot portion P to a position beyond the rear leak-proof groove 83, and vertically traverses the rear leak-proof groove 83 in the rear portion C in the rear portion C. The coagulant arranging portion 9 extends from the front end of the front leak-proof groove 82 toward the front end of the absorber 4 by 1 cm or more, more preferably 2 cm or more, and extends by 2 cm or more and absorbs. It is more preferable that the body 4 reaches the front end. Further, the coagulant arranging portion 9 preferably extends 1 cm or more from the rear end of the front leak-proof groove 83 toward the rear end of the absorber 4, more preferably 2 cm or more, and further preferably 2 cm or more. It is more preferable that it extends and reaches the rear end of the absorber 4.

The napkin 1 of the present embodiment is used by being fixed to a crotch portion of shorts or the like in the same manner as a normal sanitary napkin.
When menstrual blood is excreted in the excretion spot P of the napkin 1 during use, if it is a small amount, it is absorbed by the absorber 4 from the excretion spot P, but if it is repeatedly excreted or the amount of excretion is large. Of the menstrual blood separated into a blood cell agglutinin and a liquid component (plasma component) with less redness by contact with the blood cell agglutinant, the low-viscosity plasma component has priority and the lateral leak-proof groove 81. It flows in the vertical direction X along the above, flows in the vertical direction X, and then is absorbed by the absorber 4.
Moreover, when the menstrual blood diffused in the vertical direction X reaches the front leak-proof groove 82 or the rear leak-proof groove 83, the reddish hemagglutination is captured by the front leak-proof groove 82 or the rear leak-proof groove 83. Then, the liquid component (plasma component) having less redness diffuses beyond the anterior leak-proof groove 82 or the rear leak-proof groove 83. The liquid component (plasma component) with less redness does not cause redness even if it diffuses near the end of the absorber of the napkin 1, so that the user who sees the napkin 1 after use can see the liquid from the end. Don't worry or worry that it may have leaked. Moreover, in the case of an absorber containing a super absorbent polymer, the liquid component (plasma component) that diffuses beyond the front leak-proof groove 82 or the rear leak-proof groove 83 reduces the liquid absorbency on the surface of the water-absorbent polymer. Since it does not form a film of blood cell agglomerates that can be a cause, it is efficiently absorbed by the water-absorbent polymer, and liquid leakage from the vertical end of the absorber 4 is unlikely to occur. Further, since the front leak-proof groove 82 and the rear leak-proof groove 83 extend in the lateral direction Y, respectively, the plasma component is guided in the lateral direction Y, and in some cases, the plasma component is transmitted through the lateral leak-proof groove 81 to the front portion and the rear portion. Since it may be guided from the portion to the portion facing the excretion portion B, liquid leakage from the vertical end portion of the absorber 4 is more likely to occur.
Due to such an action, according to the napkin 1 of the present embodiment, it is possible to suppress liquid leakage from both ends in the horizontal direction of the absorber, and the absorbent body is excellent in diffusivity of the liquid in the vertical direction. It is possible to effectively utilize the absorption capacity of the absorber, and it is possible to prevent the user from being anxious about leakage due to the redness of the blood cell agglomerates near the vertical end of the absorber. The absorption capacity of the absorber is the overall absorption capacity of the absorber, including the potential absorption capacity of the portion that is originally capable of absorbing the liquid but does not absorb the liquid due to the fact that the liquid does not reach the liquid.

The fact that the blood cell aggregating agent is arranged so as not to reach both ends of the absorber 4 in the lateral direction Y has an advantage of reducing the redness of the agglomerates due to the aggregation of blood cells on the side portion of the napkin. From the viewpoint of ensuring that such an advantage or effect can be obtained more reliably, the coagulant arranging portion 9 and the coagulant arranging portion 9 are formed in the vertically central portion of the excretion portion facing portion B, particularly the excretion portion facing portion B where the excretion spot portion P is located. The distance Ln in the lateral direction Y between both ends 4S and 4S in the lateral direction Y of the absorber 4 is preferably 10% or more, more preferably 20% or more of the total width W4 of the lateral direction Y of the absorber 4 at the site. % Or more, preferably 40% or less, more preferably 30% or less, and preferably 10% or more and 40% or less, more preferably 20% or more and 30% or less.
Further, from the viewpoint of diffusing menstrual blood in the vertical direction X and increasing the utilization efficiency of the absorber, agglomeration occurs in the excretion portion facing portion B, particularly in the vertical central portion of the excretion portion facing portion B where the excretion spot portion P is located. The length L9 of the agent arrangement portion 9 in the lateral direction Y is preferably 60% or more, more preferably 70% or more, and preferably 90% or less of the total width W4 of the absorber 4 in the lateral direction at the site. , More preferably 80% or less, preferably 60% or more and 90% or less, and more preferably 70% or more and 80% or less.

Further, from the viewpoint of effectively utilizing the absorption capacity of the absorber 4 in a wide range in the vertical direction X, the front leak-proof groove 82 is provided in the front portion A located in front of the front end of the wing portion 7, as shown in FIG. It is preferable that the blood cell flocculant is formed and is arranged from the excretion spot portion P to a position beyond the position of the anterior leak-proof groove 82 as shown in FIG. It is preferable that at least a part of the front leak-proof groove 82 that the flocculant arranging portion 9 traverses is located in the front portion A, and it is preferable that the entire front leak-proof groove 82 is located in the front portion A.
Further, from the viewpoint of effectively utilizing the absorption capacity of the absorber 4 in a wide range in the vertical direction X, the rear leak-proof groove 83 is a rear portion C located behind the rear end of the wing portion 7, as shown in FIG. As shown in FIG. 3, it is preferable that the blood cell flocculant is arranged from the excretion spot portion P to a position beyond the position of the rear leakage prevention groove 83 thereof. It is preferable that at least a part of the rear leakage prevention groove 83 that the coagulant arranging portion 9 traverses is located in the rear portion C, and it is preferable that the entire rear leakage groove 83 is located in the rear portion C.

From the viewpoint of ensuring that one or more of the above-mentioned effects are more reliably exerted, the member on which the blood cell flocculant is arranged, such as the skin-side core wrap sheet 42a, is the member in the vertical direction X of the flocculant arranging portion 9. The length is preferably 50% or more, more preferably 60% or more, preferably 100% or less, more preferably 90% or less, based on the total length L4 of the absorber 4 in the longitudinal direction X. It is preferably 50% or more and 100% or less, and more preferably 60% or more and 90% or less.
Further, in the absorber 4, the total length L4 in the vertical direction X is usually longer than the maximum length in the horizontal direction Y, and the length of the coagulant arranging portion 9 is also usually longer in the vertical direction X than the length in the horizontal direction Y. The length of the coagulant arranging portion 9 in the vertical direction X is preferably 1.5 times or more, more preferably 2 times or more, and preferably 10 times or less, more preferably 5 times the length in the horizontal direction Y. It is less than or equal to, preferably 1.5 times or more and 10 times or less, and more preferably 2 times or more and 5 times or less.

In the napkin 1 of the present embodiment, as shown in FIG. 3, central arc-shaped portions 81b of the lateral leakage-proof groove 81 are formed on both sides of the vertical center line CL in the excretion portion facing portion B, and lateral to the central arc-shaped portion 81b. A second lateral leak-proof groove 84 is formed on the outer side in the direction. The coagulant arranging portion 9 of the skin-side core wrap sheet 42a has reached the side leakage-proof groove 81, but has not reached the second side leakage-proof groove 84.
As in the present embodiment, the second lateral leak-proof groove 84 is provided on the outside of the lateral leak-proof groove 81, and the blood cell flocculant is present in the second lateral leak-proof groove on each of the left and right sides of the excretion spot portion P. When arranged only inside the 84, the agglomerates generated by the aggregation of blood cells are effectively trapped in the side leakage groove 81 and the second side leakage groove 84, and the redness on the side of the napkin is reduced. can.

Further, as shown in FIG. 3, each of the left and right sides of the excretion spot portion P has a portion where the blood cell flocculant reaches the lateral leak-proof groove 81 and does not reach the second lateral leak-proof groove 84. Is also good. When such a site is provided in the excretion portion facing portion B, the plasma component separated by the aggregation of blood cells is effectively diffused in the longitudinal direction X of the absorber, so that the absorber utilization efficiency is improved.

As shown in FIG. 4, it is also preferable that the blood cell flocculant is arranged only inside the lateral leak-proof groove 81 on each of the left and right sides of the excretion spot portion P. Since the blood cell agglutinant is not present at the site overlapping the lateral leak-proof groove 81, the blood cell agglutinin is less likely to accumulate in the lateral leak-proof groove 81, and the diffusibility of menstrual blood or plasma in the longitudinal direction X is improved. do.
Such an effect is similarly exhibited even when the second side leakage prevention groove 84 is not provided.
Two or more leak-proof grooves extending in the vertical direction Y, such as the lateral leak-proof groove 81 and the second side leak-proof groove 84 shown in FIGS. 1 and 4, are provided on both sides of the excretion spot portion P, respectively. If it is provided, the leak-proof groove on the inner side in the lateral direction Y, which is close to the excretion spot portion P, is referred to as the lateral leak-proof groove 81, and the leak-proof groove on the outer side in the lateral direction Y is referred to as the second lateral leak-proof groove 84. In FIG. 4, the same components as those of the component of the napkin 1 shown in FIG. 1 are designated by the same reference numerals.

In the side leak-proof grooves 81, 81 of the napkin 1 of the present embodiment, the ends on the front portion A side are connected to each other via the front leak-proof groove 82, and the entire front leak-proof groove 82 or one of the front leak-proof grooves 82 is connected. The coagulant arranging portion 9 described above traverses the portion. As a result, the menstrual blood that is excreted in the excretion spot portion P and diffuses in the plane direction is efficiently carried to the portion of the anterior leak-proof groove 82 that overlaps with the coagulant arrangement portion 9, thereby from the front end of the absorber 4. It is possible to more efficiently prevent liquid leakage and redness near the front end.
Further, in the side leak-proof grooves 81 and 81 in the napkin 1 of the present embodiment, the ends on the rear portion C side are connected to each other via the rear leak-proof groove 83, and the entire rear leak-proof groove 83 or the rear leak-proof groove 83 is connected. A part of the coagulant arranging portion 9 described above traverses the section. As a result, the menstrual blood that is excreted in the excretion spot portion P and diffuses in the plane direction is efficiently carried to the portion of the rear leak-proof groove 83 that overlaps with the coagulant arrangement portion 9, and thereby from the rear end of the absorber 4. It is possible to more efficiently prevent the leakage of liquid and the occurrence of redness near the rear end.
Further, in any case, the plasma component separated by the blood cell flocculant is easily transferred from the anterior leak-proof groove 82 and the rear leak-proof groove 83 extending in the lateral direction Y to the lateral leak-proof groove 81. , The plasma component is easily moved to the side facing the excretion portion B in the vertical direction Y, and the entire surface of the absorber can be easily utilized as the absorption region, so that the suppression of liquid leakage is further improved.
From the viewpoint of preventing liquid leakage from the front and rear ends of the absorber 4 and redness at both ends of the absorber 4 in the vertical direction, the front leak-proof groove 82, the side leak-proof groove 81, and the rear leak-proof groove 83 are As shown in FIG. 3, it is more preferable that the annular leak-proof groove 80 is continuously formed.

In the present invention, the side leak-proof groove 81, the front leak-proof groove 82, the rear leak-proof groove 83, and the second side leak-proof groove 84 are integrally embossed on the surface sheet 2 and the absorber 4 as described above. Although it can be formed by processing, these leak-proof grooves are preferably leak-proof grooves having a high-pressure squeezed portion and a low-pressure squeezed portion at the bottom. Various known arrangement modes of the high-pressure squeezing portion and the low-pressure squeezing portion provided on the bottom portion can be used without particular limitation. FIG. 5 shows some examples of the leak-proof groove 8 provided with the high-pressure squeezing portion 8b and the low-pressure squeezing portion 8c on the bottom portion 8a. Each of the leak-proof grooves shown in FIGS. 1 and 5 uses an embossed roll having a convex portion for forming a high-pressure squeezed portion 8b that further protrudes from the tip of a convex portion provided on the outer peripheral surface thereof. The surface sheet and the absorber are integrally heated and pressurized between the embossed roll and the anvil roll.

When the leak-proof groove has a high-pressure squeezing portion and a low-pressure squeezing portion at the bottom thereof, it is possible to improve the diffusivity of plasma components and the catchability of blood cell aggregates that cause redness at the same time. Therefore, if the side leak-proof groove 81, the second side leak-proof groove 84, the front leak-proof groove 82, and the rear leak-proof groove 83 have a high-pressure squeezing portion and a low-pressure squeezing portion at the bottom, they are generated by aggregation of blood cells. The agglomerates are trapped in both the high-pressure and low-pressure squeezed sections, but the plasma components can pass through the low-pressure squeezed section and diffuse to the outside of the anterior leak-proof groove 82 and the rear leak-proof groove 83.

As the blood cell flocculant used in the present invention, one having an action of agglutinating red blood cells in blood is used. The blood cell flocculant used in the present invention is preferably capable of agglutinating erythrocytes in blood to form erythrocyte agglutinates and separating from plasma components, and preferably has the following properties. That is, when 1000 ppm of the measurement sample agent is added to the simulated blood, at least two or more erythrocytes aggregate to form an agglutinating mass while maintaining the fluidity of the blood. The simulated blood has a viscosity of 8 mPa · s measured using a B-type viscometer (model number TVB-10M manufactured by Toki Sangyo Co., Ltd., measurement conditions: rotor No. 19, 30 rpm, 25 ° C., 60 seconds). In addition, the blood cell / plasma ratio of defibered horse blood (manufactured by Japan Biotest Research Institute Co., Ltd.) was prepared.
Details of such a blood cell flocculant are described in Japanese Patent Application Laid-Open No. 2017-1151313, and various substances described as blood flocculants in the publication can be used as the blood cell flocculant of the present invention.

The blood cell flocculant preferably contains a cationic polymer. Examples of the cationic polymer include cationized cellulose and cationized starch such as hydroxypropyltrimonium chloride starch. The blood cell flocculant may also contain, as the cationic polymer, a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensate. In the present invention, the "quaternary ammonium salt" includes a compound having a positive monovalent charge at the position of the nitrogen atom or a compound that generates a positive monovalent charge at the position of the nitrogen atom by neutralization. Specific examples thereof include a salt of a quaternary ammonium cation, a neutralized salt of a tertiary amine, and a tertiary amine having a cation in an aqueous solution. The "quaternary ammonium moiety" described below is also used with the same meaning, and is a site that is positively charged in water. Further, in the present invention, the "copolymer" is a polymer obtained by copolymerizing two or more kinds of polymerizable monomers, and is a binary copolymer and a ternary or more copolymer. Includes both things. In the present invention, the "polycondensate" is a polycondensate obtained by polymerizing a condensate composed of two or more kinds of monomers. When the blood cell flocculant contains, as the cationic polymer, a quaternary ammonium salt homopolymer and / or a quaternary ammonium salt copolymer and / or a quaternary ammonium salt polycondensate, the blood cell flocculant is the first. It may contain any one of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer and a quaternary ammonium salt polycondensate, or any combination of two or more. May be good. Further, the quaternary ammonium salt homopolymer may be used alone or in combination of two or more. Similarly, the quaternary ammonium salt copolymer may be used alone or in combination of two or more. Similarly, as the quaternary ammonium salt polycondensate, one type may be used alone or two or more types may be used in combination. In addition, in this specification, a "blood cell agglutinating agent" is a compound capable of agglutinating blood erythrocytes or a combination thereof, and an agent that expresses erythrocyte agglutination by a combination of compounds. That is, the blood cell aggregating agent is an agent limited to those having a blood cell aggregating action. Therefore, when the blood cell flocculant contains a third component, it is expressed as a blood cell flocculant composition to distinguish it from the blood cell flocculant.

Among the various cationic polymers described above, the use of a quaternary ammonium salt homopolymer, a quaternary ammonium salt copolymer, or a quaternary ammonium salt polycondensate is particularly effective in terms of adsorptivity to erythrocytes. preferable. In the following description, for convenience, the quaternary ammonium salt homopolymer, the quaternary ammonium salt copolymer, and the quaternary ammonium salt polycondensate are collectively referred to as "quaternary ammonium salt polymer".

The cationic polymer preferably has a molecular weight of 2000 or more, more preferably 10,000 or more, and even more preferably 30,000 or more. When the molecular weight of the cationic polymer is equal to or higher than these values, entanglement of the cationic polymers between erythrocytes and cross-linking of the cationic polymers between erythrocytes sufficiently occur. The upper limit of the molecular weight is preferably 10 million or less, more preferably 5 million or less, and even more preferably 3 million or less. When the molecular weight of the cationic polymer is less than or equal to these values, the cationic polymer dissolves well in menstrual blood. The molecular weight of the cationic polymer is preferably 20 or more and 10 million or less, more preferably 2000 or more and 5 million or less, further preferably 2000 or more and 3 million or less, and 10,000 or more and 3 million or less. It is even more preferable, and it is particularly preferable that it is 30,000 or more and 3 million or less. The molecular weight referred to in the present invention is a weight average molecular weight, and the molecular weight is measured by the measuring method and measuring conditions described in paragraph [0032] of JP-A-2017-113513.

The cationic polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto. In particular, the quaternary ammonium salt polymer preferably has a structure having a main chain and a plurality of side chains bonded thereto. The quaternary ammonium moiety is preferably present in the side chain. In this case, if the main chain and the side chain are bonded at one point, the flexibility of the side chain is less likely to be inhibited, and the quaternary ammonium site present in the side chain is smoothly applied to the surface of the erythrocyte. It will be adsorbed. However, in the present invention, it is not prevented that the main chain and the side chain of the cationic polymer are bonded at two points or more. In the present invention, "bonded at one point" means that one of the carbon atoms constituting the main chain is single-bonded with one carbon atom located at the end of the side chain. .. "Bonded at two or more points" means that two or more of the carbon atoms constituting the main chain are single-bonded with two or more carbon atoms located at the ends of the side chains. say.

When the cationic polymer has a structure having a main chain and a plurality of side chains bonded to the main chain, for example, a quaternary ammonium salt polymer has a structure having a main chain and a plurality of side chains bonded to the main chain. In the case of, the number of carbon atoms in each side chain is preferably 4 or more, more preferably 5 or more, and even more preferably 6 or more. The upper limit of the number of carbon atoms is preferably 10 or less, more preferably 9 or less, and even more preferably 8 or less. For example, the number of carbon atoms in the side chain is preferably 4 or more and 10 or less, more preferably 5 or more and 9 or less, and further preferably 6 or more and 8 or less. The carbon number of the side chain is the carbon number of the quaternary ammonium moiety (cation moiety) in the side chain, and even if carbon is contained in the anion which is a counterion, the carbon is counted. Not included. In particular, among the carbon atoms in the side chain, the number of carbon atoms from the carbon atom bonded to the main chain to the carbon atom bonded to the quaternary nitrogen is in the above range, that is, the quaternary ammonium salt. It is preferable because the steric hindrance when the polymer is adsorbed on the surface of the erythrocyte is reduced.

In addition to the polycation (cationic polymer), the blood cell flocculant used in the present invention contains one other component such as a solvent, a plasticizer, a fragrance, an antibacterial / deodorant, and a skin care agent. It may be in the form of a composition (blood cell flocculant composition) containing the above. As the solvent, water, a water-soluble organic solvent such as a saturated aliphatic monohydric alcohol having 1 to 4 carbon atoms, or a mixed solvent of the water-soluble organic solvent and water can be used. As the plasticizer, glycerin, polyethylene glycol, propylene glycol, ethylene glycol, 1,3-butanediol and the like can be used. As the fragrance, a fragrance having a green herbal-like fragrance described in Japanese Patent No. 4776407, a plant extract, a citrus extract and the like can be used. The antibacterial / deodorant is polymerized from a canclinite-like mineral containing an antibacterial metal described in Japanese Patent No. 4526271 and a polymerizable monomer having a phenyl group described in Japanese Patent No. 45879928. Porous polymers, quaternary ammonium salts described in Japanese Patent No. 4651392, activated carbon, clay minerals and the like can be used. As the skin care agent, a plant extract, collagen, a natural moisturizing ingredient, a moisturizer, a keratin softening agent, an anti-inflammatory agent and the like described in Japanese Patent No. 4084278 can be used.

The proportion of the cationic polymer in the blood cell flocculant composition is preferably 1% by mass or more, more preferably 3% by mass or more, and further preferably 5% by mass or more. Further, it is preferably 50% by mass or less, more preferably 30% by mass or less, and further preferably 10% by mass or less. By setting the ratio of the cationic polymer to the blood cell flocculant composition within this range, an effective amount of the cationic polymer can be imparted to the absorbent article.

Examples of the blood cell flocculant include water-soluble cationic polymers.
With respect to the water-soluble cationic polymer, "water-soluble" means that 0.05 g of a powder of 1 mm or less or a film-like cationic polymer having a thickness of 0.5 mm or less is placed in a 100 mL glass beaker (5 mmΦ) at 25 ° C. and 50 mL ions. When added and mixed with exchanged water, a stirrer chip with a length of 20 mm and a width of 7 mm is put in, and the entire amount dissolves in water within 24 hours under stirring at 600 rpm using a magnetic stirrer HPS-100 manufactured by AS ONE Co., Ltd. That is. As a more preferable solubility, the total amount is preferably dissolved in water within 3 hours, and the total amount is more preferably dissolved in water within 30 minutes.

The amount of the blood cell flocculant per unit area (hereinafter, also referred to as basis weight) of the flocculant arranging portion 9 is preferably 2 g / m ² or more, more preferably 4 g / m ² or more, and preferably 20 g / m 2 or more. It is m ² or less, more preferably 10 g / m ² or less, and 2 g / m ² or more and 20 g / m ² or less, more preferably 4 g / m ² or more and 10 g / m ² or less.
The amount of the hemagglutin agent referred to here is the net amount of the cationic polymer when the hemagglutin agent is a cationic polymer, and the amount of the hemagglutin agent per unit area is, for example, as follows. Is required.
[Measuring method]
After arranging the solution in which the cationic polymer was dissolved, it was allowed to stand for 24 hours under the condition of 30 ° C. and 10% RH to dry, and the coagulant-arranged portion was cut out and the area was measured before and after the coagulant arrangement. By comparing the weights, it is calculated as the abundance of the blood cell flocculant per unit area contained after drying.

Although the present invention has been described above, the present invention is not limited to the above-described embodiments, and can be appropriately modified without departing from the spirit of the present invention. For example, instead of the ventral core wrap sheet, the blood cell flocculant may be arranged on the surface sheet 2 or the sublayer in the manner shown in FIG. 3 or FIG.

Further, the absorbent article of the present invention may not have the second lateral leakage-proof groove 84, and the blood cell flocculant may be present from the excretion spot P to the front leakage-proof groove 82 and the rear leakage-proof groove 83. It may be arranged up to a position exceeding only one of them. Further, the front leak-proof groove 82 and the rear leak-proof groove 83 may be one or both of which are not continuous with the side leak-proof groove 81.
Further, the absorbent article of the present invention may not have a side leak-proof sheet and a leak-proof mechanism by the side leak-proof sheet, or may not have a wing portion. Further, the absorbent article of the present invention may be a panty liner (pantyliner) or the like in addition to a sanitary napkin.

Hereinafter, the present invention will be described in more detail with reference to Examples. However, the scope of the present invention is not limited by such examples.
[Example 1]
A sanitary napkin having the same configuration as the sanitary napkins shown in FIGS. 1 and 2 was prepared, and this was used as the sanitary napkin of Example 1. An air-through non-woven fabric having a basis weight of 30 g / m ² is used as the front sheet, a non-breathable polypropylene film having a basis weight of 28 g / m ² is used as the back sheet, and a basis weight of 20 g / m is used as the side leakage-proof sheet. The spunbonded non-woven fabric of ^{2 was used.} The absorber is a mixed product of pulp fibers having a basis weight of 280 g / m ² and a highly absorbent polymer coated with a core wrap sheet, and has a length of 186 mm in the vertical direction and a length of 70 mm in the horizontal direction. Was used.
The core wrap sheet is a sheet base material made of cellulose fibers having a basis weight of 16 g / m ² , and a hemagglutinant is applied to a portion of the absorbent core on the skin-facing surface side, as shown in FIGS. 2 and 3. After coating so as to be distributed in, the dried one was used. In the obtained core wrap sheet, a coagulant arranging portion 9 having ^{a cationic polymer basis weight of 6 g / m 2} was formed in the lateral central portion of the portion covering the skin-facing surface side of the absorbent core.
As the blood cell flocculant, "PAS-H-5L" manufactured by Nittobo Medical Co., Ltd. was used. This blood cell flocculant contains polyDADMAC (weight average molecular weight: 30,000), which is a water-soluble quaternary ammonium salt homopolymer.

[Comparative Example 1]
The coating width of the blood cell flocculant is the same as in Example 1, and the vertical range of the absorber to which the blood cell flocculant is applied is set from a position 10 mm inside the anterior leak-proof groove to 10 mm inside the rear leak-proof groove. A sanitary napkin of Comparative Example 1 was prepared in the same manner as in Example 1 except that the position was up to the position.

[Comparative Example 2]
A sanitary napkin of Comparative Example 2 was prepared in the same manner as in Example 1 except that the core wrap sheet was not coated with a blood cell flocculant at all on the sheet base material.

〔evaluation〕
For each of the sanitary napkins of Examples and Comparative Examples, the absorption performance, the degree of utilization of the absorption capacity of the absorber, and the suppressiveness of redness at the end of the napkin were evaluated by the following methods, and the results thereof. Is shown in Table 1.

<Absorption performance>
The dynamic maximum absorption amount was measured by the following method, and the absorption performance was evaluated according to the following evaluation criteria based on the measurement result.
(Measurement method of dynamic maximum absorption amount)
The sanitary napkin to be evaluated was fixed to the sanitary shorts and attached to a dynamic model of the human body. As a dynamic model of the human body, a movable female lumbar model capable of walking and moving both legs was used. The walking motion of the dynamic model was started, and 1 minute after the start of the walking motion, 2 g of pseudo blood was injected from the liquid excretion point (first time). Further, 3 g of pseudo blood was injected 3 minutes after the completion of the first liquid injection (second time). Furthermore, 2 g of pseudo blood was injected 3 minutes after the completion of the second liquid injection (third time). From the third time onward, the operation of injecting 2 g of pseudo blood 3 minutes after the liquid injection is repeated, and the liquid injection operation is completed when the pseudo blood exudes from the wing part of the sanitary napkin, and injection is performed by that time. The total weight of the simulated blood was taken as the dynamic maximum absorption amount.
The viscosity of the simulated blood is 8 mPa · s measured using a B-type viscometer (model number TVB-10M manufactured by Toki Sangyo Co., Ltd., measurement conditions: rotor No. 19, 30 rpm, 25 ° C., 60 seconds). , The blood cell / plasma ratio of defibered horse blood (manufactured by Japan Biotest Research Institute Co., Ltd.) was prepared and used.

(Evaluation criteria)
For each sanitary napkin, the absorption performance was evaluated according to the following criteria based on the measured value of the dynamic maximum absorption amount. It is shown that the larger the dynamic maximum absorption amount, the better the absorption performance of menstrual blood.
A: Dynamic maximum absorption amount 13 g or more B: Dynamic maximum absorption amount less than 13 g

<Degree of utilization of absorption capacity of absorber>
The diffusion area of the absorber was measured by the following method, and based on the measurement results, the degree of utilization of the absorption capacity of the absorber was evaluated according to the following evaluation criteria.
(Measurement method of absorber diffusion area)
Each sanitary napkin was fixed to an acrylic plate, 3 g of pseudo blood was injected into the place corresponding to the drainage spot P, allowed to stand for 3 minutes from the end of the liquid injection, and 3 g of pseudo blood was injected again after standing for 3 minutes. .. After repeating this operation of pseudo-blood and standing for 3 minutes until 9 g of blood is injected, observe from the surface sheet side, measure the area of the part where menstrual blood is spreading in the absorber, and measure the area of the absorber diffusion area. And said.

(Evaluation criteria)
For each sanitary napkin, the degree of utilization of the absorption capacity of the absorber was evaluated based on the absorption area of the absorber according to the following criteria. The larger the diffusion area of the absorber, the higher the absorption material of the absorber is used for absorption and the higher the degree of utilization of the absorption capacity of the absorber. However, if the diffusion area of the absorber is ^{more than 70 cm 2} , it may reach the end portion in the longitudinal or width direction of the absorber, which indicates that the possibility of liquid leakage from the absorber increases. ..
A: Absorbent diffusion area is 50 cm ² or more and 70 cm ² or less B: Absorbent diffusion area is less than ^{50 cm 2}

<Inhibitory of redness at the end of the napkin>
Each sanitary napkin is fixed to a horizontally arranged acrylic plate, 3 g of pseudo blood is injected from the part corresponding to the excretion spot P, allowed to stand for 3 minutes from the end of liquid injection, and after standing for 3 minutes, 3 g of simulated blood is again injected. Blood was injected. This operation of pseudo-blood and standing for 3 minutes is repeated until 9 g of blood is injected, and then using a color difference meter, the portion corresponding to the excretion spot portion P (the center of the excretion portion facing portion B in the vertical direction and the horizontal direction). ^{The L *} value a ^* value was measured for each of the part) and the vertical end of the absorber at the position corresponding to the excretion spot part P and the position in the horizontal direction Y, and the redness was confirmed. As the color difference meter, NF333 manufactured by Nippon Denshoku Kogyo Co., Ltd. was used.

(Evaluation criteria)
For each sanitary napkin, the inhibitory ability of redness at the end of the napkin was evaluated based ^{on the L *} value a ^* value at the vertical end of the absorber according to the following criteria. The larger the L * value at the end, the more excellent the ability to suppress the development of redness at the vertical end of the napkin.
〇: L ^* value 65 or more and a ^* value less than 5 Δ: L ^* value 60 or more and less than 65, or a ^* value 5 or more and less than 10 ×: L ^* value less than 60, or a ^* value 10 or more

According to the results in Table 1, the sanitary napkin of Example 1 was compared with the sanitary napkin of Comparative Example 2 in terms of absorption performance, degree of effective utilization of the absorption capacity of the absorber, and at the end of the absorber. Both of the suppressive properties of redness development are improved, and compared with the sanitary napkin of Comparative Example 1, the degree of effective utilization of the absorption capacity of the absorber and the suppression of redness development at the end of the absorber. The sex is improving. Therefore, by arranging the blood cell flocculant from the excretion spot portion to a position beyond the anterior leak-proof groove or the rear leak-proof groove, the absorption performance can be improved and the redness at the end of the absorber can be improved. It can be seen that the expression of the substance can be suppressed and the absorption capacity of the absorber can be effectively utilized.

1 Sanitary napkin (absorbent article)
2 Front sheet 3 Back sheet 4 Absorbent 41 Absorbent core 42 Core wrap sheet 42a Skin side core wrap sheet (Core wrap sheet that covers the skin facing side of the absorbent core)
5 Absorbent body 6 Side leak-proof sheet 7 Wing part 8 Leak-proof groove 81 Side leak-proof groove 82 Front leak-proof groove 83 Rear leak-proof groove 84 Second side leak-proof groove 9 Coagulant placement part A Front part B Excretion Opposing part P Excretion spot part C Rear part

Claims (7)

It is provided with a liquid-permeable front surface sheet forming a skin-facing surface, a back surface sheet forming a non-skin-facing surface, and an absorber arranged between these two sheets, and is provided in the vertical direction along the front-rear direction of the wearer and the vertical direction. An absorbable article for menstrual blood absorption having a lateral direction orthogonal to
As a leak-proof groove in which the surface sheet and the absorber are integrally recessed, the liquid excretion portion of the wearer is formed on both the left and right sides of the excretion spot portion arranged to face each other, and each extends in the vertical direction. It has a one-way leak-proof groove and front and rear leak-proof grooves formed in front of and behind the excretion spot portion and extending in the lateral direction, respectively.
A hemagglutinant is arranged on a member that forms a surface of the absorber on the skin-facing surface side or is located on the skin-facing surface side of the absorber, and the hemagglutinant is used in the lateral direction. , Existing in the excretion spot portion and not reaching both ends of the absorber in the lateral direction, and in the vertical direction, existing in the excretion spot portion and of the anterior and posterior leak-proof grooves. Absorbent articles that are placed beyond at least one side. The absorbent article has a pair of wing portions, and the front leak-proof groove and the rear leak-proof groove are located in front of the front end of the wing portion and rearward of the rear end of the wing portion. The absorbent article according to claim 1, which is formed in a rear portion thereof. A second lateral leak-proof groove extending along the lateral leak-proof groove is provided outside the lateral leak-proof groove in the lateral direction, and the blood cell flocculant is left and right of the excretion spot portion. The absorbent article according to claim 1 or 2, which is arranged only inside the second lateral leakage-proof groove on each side. The absorbable article according to claim 1 or 2, wherein the blood cell flocculant is arranged only inside the lateral leak-proof groove on each of the left and right sides of the excretion spot portion. Any one of claims 1 to 4, wherein the side leak-proof groove and the front leak-proof groove are continuous, or the side leak-proof groove and the rear leak-proof groove are continuous. Absorbent article described in. Claims 1 to 1 of the front leak-proof groove and the rear leak-proof groove, wherein the leak-proof groove in which the blood cell flocculant exists beyond the leak-proof groove and the side leak-proof groove are continuous. The absorbent article according to any one of 4. The absorbent article according to any one of claims 1 to 6, wherein the leak-proof groove has a high-pressure squeezing portion and a low-pressure squeezing portion at the bottom.

Images